Oro-Facial Dyskinesias and Amodiaquine

Kamagaté, Mamadou; Die-Kacou, H.; Balayssac, Éric; Daubret, Potey-Thérèse; Yavo, J. C.

doi:10.2515/therapie:2004097

Cited by 7 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Extrapyramidal syndrome‐related oral manifestations were frequently reported after receiving amodiaquine, most of which initiated with tremor of the tongue and facial muscles, hypersalivation, and subsequently presented protrudence of tongue (Akindele & Odejide, 1976; Kamagate et al., 2004); some patients occasionally complained muscular facial pain, masseter muscles contracture with grinding teeth, sudden opening of the mouth and difficulty in closing the mouth, speaking difficulty, and stiff neck (Kamagate et al., 2004). Moreover, cutaneous and mucosal pigment depositions on hard palate (Maguire, 1962; McAllan & Adkins, 1986), face, and neck (Watson & MacDonald, 1974) were also prevalent in patients exposed to amodiaquine.…”

Section: Oral‐maxillofacial Adverse Events Related To Antimlarialsmentioning

confidence: 99%

“…Therefore, understanding of antimalarial‐related adverse events might be very important for general and specific professionals to manage such adverse events. Oral‐maxillofacial manifestations were a type of common adverse events related to antimalarials and always accompanied with some severe adverse events of extrapyramidal syndrome (Kamagate, Die‐Kacou, Balayssac, Daubret, & Yavo, 2004) and cutaneous lesions (Nitta, Kano, Ushigome, Hayakawa, & Shiohara, 2019) as early symptoms. Some patients might complain for their oral‐maxillofacial disorders at primary visit to clinics.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Oral‐maxillofacial adverse events related to antimalarials

Wang

Jiang

et al. 2020

Oral Diseases

View full text Add to dashboard Cite

Malaria is a worldwide parasitic disease, which affects millions of lives every year. Various medications are recommended by WHO for prevention and treatment of malaria. However, adverse events caused by antimalarials were frequently reported, some of which were severe and fatal. Disorders of many organs related to antimalarials have been well recognized, whereas few studies concentrated on the relationship between antimalarials and oral‐maxillofacial system health. Current review generalized the relevance of antimalarials to the health of oral‐maxillofacial part and raised an urgent need to form a standard management for antimalarial‐related oral‐maxillofacial adverse events.

show abstract

Section: Oral‐maxillofacial Adverse Events Related To Antimlarialsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Oral‐maxillofacial adverse events related to antimalarials

Wang

Jiang

et al. 2020

Oral Diseases

View full text Add to dashboard Cite

show abstract

“…Apart from agranulocytosis and hepatitis, several cases of acute dystonic reactions [Akindele and Odejide, 1976;Akpalu et al, 2005;Kamagate et al, 2004], and bradycardia [Ngouesse et al, 2001] have been ascribed to amodiaquine treatment, but mainly in adults.…”

Section: Amodiaquinementioning

confidence: 99%

Artesunate plus amodiaquine combination therapy: reviewing the evidence

Adjei

Kudzi

Dodoo

et al. 2009

Drug Development Research

View full text Add to dashboard Cite

The combination of artesunate plus amodiaquine (AS/AQ) is, next to the fixed-dose combination of artemether-lumefantrine, the most widely adopted artemisinin combination therapy (ACT) regimen being used as first-line therapy for uncomplicated malaria by National Malaria Control Programs in sub-Saharan Africa. In contrast to other ACT regimens in current use, on which reviews of the available evidence on safety and efficacy have been periodically published, no, or few summaries of the extensive data available on the safety and efficacy of this widely used ACT are available in the published literature. The available evidence on AS/AQ indicates high efficacy of this combination in children, variable tolerability in adults, and an interaction between artesunate and amodiaquine that could have implications for medium term efficacy or safety of the combination. In this article, a review of the available evidence on the efficacy and safety on AS/AQ, with a particular focus on parameters that could have operational significance for malaria control in endemic areas, is presented and discussed. Drug Dev Res 71:33-43, 2010.

show abstract

“…Amodiaquine-associated dystonic reaction was first reported from Nigeria in 1976. 4 Since then, there has been a paucity of similar reports in the published literature until recently, when a series of such cases were reported from Cote d'Ivoire (in 2004) 5 and from Ghana (in 2005). 6 The mechanism underlying the well-known side effects of amodiaquine (agranulocytosis and hepatitis) is direct toxicity 7 , or immune-mediated hypersensitivity.…”

Section: Introductionmentioning

confidence: 99%

Amodiaquine-associated adverse effects after inadvertent overdose and after a standard therapeutic dose

Adjei

Goka²,

Rodrigues³

et al. 2010

Ghana Medical Journal

View full text Add to dashboard Cite

SUMMARYA case of an acute dystonic reaction in a child presumptively treated for malaria with amodiaquine, and a case of persistent asymptomatic bradycardia in another child with mild pulmonary stenosis treated with a standard dose of amodiaquine for parasitologically confirmed uncomplicated malaria, is reported. Both subjects were homozygous for the wild type allele of cytochrome P450 2C8, the main enzyme responsible for amodiaquine metabolism. In both subjects, plasma concentrations of N-desethylamodiaquine and N-bisdesethylamodiaquine, the main metabolites of amodiaquine, were normal. No other drugs were detectable in the plasma of these two subjects after further toxicological screening. These observations, which suggest altered metabolism in the subject with an acute dystonic reaction, support the assertion that amodiaquine-associated dystonia is an idiosyncratic reaction. However, the occurrence of bradycardia after a standard dose of amodiaquine, which coincided with the time of expected peak concentrations of the active metabolite of amodiaquine, suggests a direct drug effect. These less reported adverse effects are likely to increase in parallel with the increased use of amodiaquine as a partner drug for combination therapy of malaria in Ghana. Further studies aimed at elucidating the mechanisms underlying these effects are, therefore, required.

show abstract

Oro-Facial Dyskinesias and Amodiaquine

Cited by 7 publications

References 5 publications

Oral‐maxillofacial adverse events related to antimalarials

Oral‐maxillofacial adverse events related to antimalarials

Artesunate plus amodiaquine combination therapy: reviewing the evidence

Amodiaquine-associated adverse effects after inadvertent overdose and after a standard therapeutic dose

Contact Info

Product

Resources

About